Mucosis BV has signed a research and license option agreement with Crucell Holland B.V., under which Crucell will use Mucosis’ Mimopath platform technology to develop vaccines for infectious diseases. Mucosis will receive upfront payments and is eligible to receive achievement-based milestones. Financial terms were not disclosed.   “We are delighted to collaborate with Crucell as we strongly believe that our Mimopath platform combined with Crucell’s expertise in vaccine develop...